Work

Nonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia

Year: 2015

Type: article

Abstract: Allogeneic stem cell transplantation (allo-SCT) is an effective treatment modality for acute myeloid leukemia (AML) that exerts its therapeutic benefit via a graft versus leukemia effect. 1 Its applicability is limited by toxicity from preconditioning chemoradiation in addition to the threat of graft versus host disease, which precludes many patients with AML from receiving this definitive consolidative therapy. 2 Previously, we have shown an ability to generate responses, some of which were complete, in patients with relapsed/refractory AML using haploidentical donor lymphocyte infusions in the absence of engraftment. 3 We present data from our FDA-approved Phase II clinical trial (BrUOG H-273, IND 015008, NCT01685606) in which haploidentical allogeneic cells are infused. Unlike our previous trial these cellular infusions occur without granulocyte colony stimulating factor (G-CSF) mobilization or preconditioning low-dose total body irradiation (TBI). The goal is to generate a robust allogeneic response that breaks host tumor tolerance without the toxicity profile seen with allo-SCT.

Source: Blood Cancer Journal

DOI: 10.1038/bcj.2015.100